CCR2-targeted cancer nanoimmunotherapy

by | Mar 2, 2022 | Lim, Kian-Huat, Liu, Yongjian, Zhang, Xiaohui

— Disease indication –

Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide

Drug class – First-in-class

Target – CCR2, the receptor for CCL2

Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…